Renerve Ltd

Healthcare AU RNV

0.076AUD
-0.005(6.17%)

Last update at 2026-06-26T06:10:00Z

Day Range

0.070.08

LowHigh

52 Week Range

0.070.22

LowHigh

Fundamentals

Previous Close 0.08
Market Cap13.96M
Volume42216
P/E Ratio-
Dividend Yield-%
EBITDA-5.18305M
Revenue TTM0.33M
Revenue Per Share TTM0.002
Gross Profit TTM 0.19M
Diluted EPS TTM-0.03

Overview
Financials
Peer Comparison
Reports
Stock Research & News
Profile

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown	2025-06-30	2024-06-30	2023-06-30	2022-06-30
Type	yearly	yearly	yearly	yearly
Date	2025-06-30	2024-06-30	2023-06-30	2022-06-30
Income before tax	-3.73392M	-2.98495M	-1.80328M	-1.75748M
Minority interest	-	-	-	-
Net income	-3.73392M	-2.98495M	-1.80328M	-1.75748M
Selling general administrative	2.89M	2.20M	1.80M	1.11M
Selling and marketing expenses	-	-	-	-
Gross profit	0.24M	0.18M	0.13M	0.58M
Reconciled depreciation	0.05M	0.15M	0.15M	0.02M
Ebit	-	-	-	-
Ebitda	-	-	-	-
Depreciation and amortization	-	-	-	-
Non operating income net other	-	-	-	-
Operating income	-4.45391M	-3.11636M	-2.19618M	-1.75599M
Other operating expenses	-	-	-	-
Interest expense	0.25M	0.29M	0.00696M	0.00149M
Tax provision	0.00000M	0.00000M	0.00000M	0.00000M
Interest income	0.14M	-	-	-
Net interest income	-0.10524M	-0.29025M	-0.00696M	-0.00149M
Extraordinary items	-	-	-	-
Non recurring	-	-	-	-
Other items	-	-	-	-
Income tax expense	-	-	-	-
Total revenue	0.27M	0.18M	0.13M	0.58M
Total operating expenses	-	-	-	-
Cost of revenue	0.03M	0.00062M	-	-
Total other income expense net	0.83M	0.42M	0.40M	-
Discontinued operations	-	-	-	-
Net income from continuing ops	-3.73392M	-2.98495M	-1.80328M	-1.75748M
Net income applicable to common shares	-	-	-	-
Preferred stock and other adjustments	-	-	-	-

Breakdown	2025-06-30	2024-06-30	2023-06-30	2022-06-30
Type	yearly	yearly	yearly	yearly
Date	2025-06-30	2024-06-30	2023-06-30	2022-06-30
Total assets	6.19M	7.92M	0.00000M	0.00000M
Intangible assets	0.02M	0.00698M	-	-
Earning assets	-	-	-	-
Other current assets	0.14M	0.08M	-	-
Total liab	1.00M	0.50M	0.00000M	0.00000M
Total stockholder equity	5.20M	7.42M	0.00000M	0.00000M
Deferred long term liab	-	-	-	-
Other current liab	0.11M	0.04M	-	-
Common stock	-	-	-	-
Capital stock	17.02M	16.67M	-	-
Retained earnings	-12.18972M	-9.68713M	-	-
Other liab	-	-	-	-
Good will	-	-	-	-
Other assets	-	-	-	-
Cash	4.75M	7.49M	-	-
Cash and equivalents	-	-	-	-
Total current liabilities	0.96M	0.48M	0.00000M	0.00000M
Current deferred revenue	-	-	-	-
Net debt	-	-	-	-
Short term debt	-	-	-	-
Short long term debt	-	-	-	-
Short long term debt total	-	-	-	-
Other stockholder equity	-	-	-	-
Property plant equipment	-	-	-	-
Total current assets	6.07M	7.82M	0.00000M	0.00000M
Long term investments	0.04M	-	-	-
Net tangible assets	-	-	-	-
Short term investments	-	-	-	-
Net receivables	0.04M	0.06M	-	-
Long term debt	-	-	-	-
Inventory	0.20M	0.18M	-	-
Accounts payable	0.41M	0.17M	-	-
Total permanent equity	-	-	-	-
Noncontrolling interest in consolidated entity	-	-	-	-
Temporary equity redeemable noncontrolling interests	-	-	-	-
Accumulated other comprehensive income	-	-	-	-
Additional paid in capital	-	-	-	-
Common stock total equity	-	-	-	-
Preferred stock total equity	-	-	-	-
Retained earnings total equity	-	-	-	-
Treasury stock	-	-	-	-
Accumulated amortization	-	-	-	-
Non currrent assets other	-	0.04M	-	-
Deferred long term asset charges	-	-	-	-
Non current assets total	0.12M	0.10M	0.00000M	0.00000M
Capital lease obligations	-	0.02M	-	-
Long term debt total	-	-	-	-

Breakdown	2025-06-30	2024-06-30	2023-06-30	2022-06-30
Type	yearly	yearly	yearly	yearly
Date	2025-06-30	2024-06-30	2023-06-30	2022-06-30
Investments	-	0.51M	-0.55739M	-0.11589M
Change to liabilities	-	-	-	-
Total cashflows from investing activities	-	-	-	-
Net borrowings	0.76M	0.91M	-	-
Total cash from financing activities	7.09M	0.82M	2.00M	1.52M
Change to operating activities	-	-	-	-
Net income	-3.73392M	-2.98495M	-1.80328M	-1.75748M
Change in cash	4.04M	-0.96757M	-0.03071M	-0.45949M
Begin period cash flow	0.71M	1.68M	1.71M	2.17M
End period cash flow	4.75M	0.71M	1.68M	1.71M
Total cash from operating activities	-	-	-	-
Issuance of capital stock	7.00M	-	2.21M	1.63M
Depreciation	-	-	-	-
Other cashflows from investing activities	-	-	-	-
Dividends paid	-	-	-	-
Change to inventory	-	-	-	-
Change to account receivables	-	-	-	-
Sale purchase of stock	-	-	-0.13785M	-0.10346M
Other cashflows from financing activities	-	-	-	-
Change to netincome	-	-	-	-
Capital expenditures	0.07M	0.00498M	0.05M	0.12M
Change receivables	-	-	-	-
Cash flows other operating	-	-	-	-
Exchange rate changes	-	-	-	-
Cash and cash equivalents changes	-	-	-	-
Change in working capital	-	-	-	-
Stock based compensation	-	-	-	-
Other non cash items	-	-	-	-
Free cash flow	-3.04925M	-2.29783M	-1.51671M	-1.97506M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company	Change (AUD)	Price (AUD)	Trailing PE (x)	Forward PE (x)	Price Sales TTM (x)	Price to Book Value (x)	Enterprise Value to Revenue (x)
RNV Renerve Ltd	-0.005 6.17%	0.08	-	-	41.88	2.72	31.37
CSL CSL Ltd	-2.78 2.36%	114.87	13.19	12.64	3.66	2.06	3.14	9.45
TLX TELIX Pharmaceuticals Ltd	-0.35 2.23%	15.33	-	2500.00	6.63	8.97	5.04	115.29
MSB Mesoblast Ltd	-0.195 9.38%	1.89	-	454.55	41.13	3.51	30.21	-9.8623
NEU Neuren Pharmaceuticals Ltd	-0.56 4.39%	12.20	55.48	51.55	25.02	4.83	20.72	60.81

Reports Covered

View All

Profile

ReNerve Limited, a medical device company, develops tissue-based products for peripheral nerve repair and replacement, and other related soft tissue surgical procedures. It develops NervAlign Nerve Cuff, a bioabsorbable protective wrap used to protect repaired nerves; and NervAlign bionic nerve and NervAlign Nerve Graft, an off-the-shelf, ready to use nerve structure for challenging nerve repairs. The company also offers deep dermal tissue product, a deep dermal product used in the repair of reconstructive and cosmetic surgical cases; amniotic tissue product ranges, used to aid the healing of wounds; NervAlign Nerve Conduit Range, a nerve conduit designed to facilitate nerve growth over short gaps between nerve ends; and NervAlign Nerve Guide Matrix for treating more severe nerve injuries, but eliminating the need for patients to undergo additional sural nerve harvesting. The company was incorporated in 2016 and is headquartered in Northcote, Australia.

Renerve Ltd

157 Heidelberg Road, Northcote, VIC, Australia, 3070

61 3 9482 3940
https://renerve.com.au

Key Executives

Name	Title	Year Born
Dr. Julian John Chick BSc (Hons)	CEO & Executive Director	1969
Dr. David Ian Rhodes	CSO & Executive Director	NA
Mr. David Lilja CTA, M.B.A.	CFO & Company Secretary	NA
Dr. Alex Adamides FRACS, M.D.	Chief Medical Officer & Member of Scientific Advisory Board	NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.